Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
Study identifier:3591IL/0082
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia
Medical condition
pneumonia
Phase
Phase 3
Healthy volunteers
No
Study drug
MERREM I.V. 2g as a 3 hour infusion every 8 hours, vancomycin I.V. 1 g every 12 hours, tobramycin I.V. 5 mg/kg every 24 hours, MERREM I.V. 1g as a 30 minute infusion every 8 hours, MERREM I.V. 500 mg as a 3 hour infusion every 8 hours
Sex
All
Actual Enrollment
500
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jul 2002
Primary Completion Date: 01 Sept 2004
Study Completion Date: 01 Sept 2004
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
